Intellia Therapeutics Newsroom

Stifel Nicolaus Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)

TipRanksJul 11 21:25

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target

BenzingaJun 27 21:39

Intellia Therapeutics Analyst Ratings

BenzingaJun 27 21:38

Intellia Therapeutics Analyst Ratings

BenzingaJun 25 01:35

Truist Securities Maintains Buy on Intellia Therapeutics, Maintains $120 Price Target

BenzingaJun 25 01:35

Cantor Fitzgerald Reiterates Overweight on Intellia Therapeutics, Maintains $65 Price Target

BenzingaJun 18 22:13

Intellia Therapeutics Analyst Ratings

BenzingaJun 18 22:12

Intellia Therapeutics Analyst Ratings

BenzingaJun 5 01:30

JMP Securities Remains a Hold on Intellia Therapeutics (NTLA)

TipRanksJun 3 05:17

Oppenheimer Keeps Their Buy Rating on Intellia Therapeutics (NTLA)

TipRanksMay 23 19:55

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Liquidia Technologies (LQDA) and Pacific Biosciences (PACB)

TipRanksMay 15 01:15

Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)

TipRanksMay 14 17:26

Citi: Maintains Intellia Therapeutics (NTLA.US) rating, adjusted from neutral to neutral, and adjusted the target price from $31.00 to $29.00.

Zhitong FinanceMay 11 05:40

Intellia Therapeutics Analyst Ratings

BenzingaMay 11 05:35

Citigroup Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $29

BenzingaMay 11 05:35

Bank of Montreal, Canada: Maintaining the Intellia Therapeutics (NTLA.US) rating, adjusted from superior to superior market rating, target price adjusted from $62.00 to $70.00.

Zhitong FinanceMay 10 23:10

Intellia Therapeutics Analyst Ratings

BenzingaMay 10 23:10

BMO Capital Maintains Outperform on Intellia Therapeutics, Raises Price Target to $70

BenzingaMay 10 23:10

Intellia Therapeutics: A Promising Buy Rating Supported by Trial Success and Strong Financials

TipRanksMay 10 20:25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Catalyst Pharma (CPRX), Xenon (XENE) and Intellia Therapeutics (NTLA)

TipRanksMay 10 19:15